GlaxoSmithKline News and Research

RSS

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals Incorporated today announced that GlaxoSmithKline was granted marketing authorization from the European Commission for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

15 Mar 2010

GAVI Alliance reaches agreement with drugmakers on reduced-price pneumococcal vaccines

Several drugmakers have reached an agreement "to supply up to 200 million doses a year of cut-price pneumococcal vaccines to developing nations," according to GAVI Alliance, Reuters reports.

15 Mar 2010

iReminder’s white paper highlights key developments in HPV vaccine compliance and marketing efforts

Automated reminder and follow-up calls for HPV vaccinations increase adherence rates from 5% to over 20%, according to a new white paper published by iReminder, LLC. The Scotland National Health Service is the leader in HPV vaccination compliance, with rates as high as 92% for the first dose and 87.8% for the second dose. The laggard is Mississippi, USA where HPV vaccination rates are as low as 15.8%.

11 Mar 2010

GSK to offer flexible drug pricing in middle-income countries

Drug maker GlaxoSmithKline (GSK) "plans to bolster earnings by selling to more people in middle-income countries after cutting prices in the world's poorest nations," Bloomberg/BusinessWeek reports.

11 Mar 2010

Cellzome, GSK form second major alliance to develop new anti-inflammatory drugs

Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.

10 Mar 2010

Exelixis fourth-quarter revenues rise from $29.6M to $44.1M

Exelixis, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009.

9 Mar 2010

GSK's Japanese subsidiary begins voluntary recall of Poligrip products containing zinc

Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.

5 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

POZEN reports net loss of $6.9M for year ended December 31, 2009

POZEN Inc., today announced results for the fourth quarter and year ended December 31, 2009.

3 Mar 2010

Intercell AG's revenues for full year 2009 increase 10.6%

Today, the biotech-vaccine company Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.

2 Mar 2010

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals, Inc. today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2 million compared with its guidance for the year of pro forma net income of more than $145 million and a pro forma NOL in the low to mid $20 million range. Isis also achieved its cash guidance by ending 2009 with $574.3 million of cash, cash equivalents and short-term investments significantly in excess of the $550 million projected.

1 Mar 2010

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail Corporation today announced financial results for the three-month and 12-month periods ending December 31, 2009.

25 Feb 2010

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

Adolor announces $14.6M net product sales of ENTEREG for year ended December 31, 2009

Adolor Corporation today reported a net loss of $47.9 million, or $(1.03) per basic and diluted share, for the year ended December 31, 2009, compared to a net loss of $30.1 million, or $(0.65) per basic and diluted share, for the year ended December 31, 2008.

25 Feb 2010

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

Today, GlaxoSmithKline responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report").

25 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

Senate, FDA reports increasing concerns about controversial diabetes drug

"Hundreds of people taking Avandia, a controversial diabetes medicine, needlessly suffer heart attacks and heart failure each month, according to confidential government reports that recommend the drug be removed from the market ... ," The New York Times reports. "The internal F.D.A. reports are part of a fierce debate within the agency over what to do about Avandia, manufactured by GlaxoSmithKline."

23 Feb 2010

UCSF professor receives 2010 AADR Distinguished Scientist Award

The American Association for Dental Research (AADR) has announced that John Greenspan, University of California, San Francisco (UCSF), is the recipient of the 2010 AADR Distinguished Scientist Award. This award will be presented to Greenspan at the 39th AADR Annual Meeting & Exhibition in Washington, DC, March 3, 2010.

20 Feb 2010

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.

19 Feb 2010

Parker Waichman Alonso applauds GSK for deciding to stop manufacturing denture adhesive products made with zinc

The attorneys of Parker Waichman Alonso LLP applaud GlaxoSmithKline for its decision to voluntarily stop the manufacture, distribution and advertising of all Super PoliGrip denture adhesive products made with zinc.

19 Feb 2010

GlaxoSmithKline News and Research

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

GAVI Alliance reaches agreement with drugmakers on reduced-price pneumococcal vaccines

iReminder’s white paper highlights key developments in HPV vaccine compliance and marketing efforts

GSK to offer flexible drug pricing in middle-income countries

Cellzome, GSK form second major alliance to develop new anti-inflammatory drugs

Exelixis fourth-quarter revenues rise from $29.6M to $44.1M

GSK's Japanese subsidiary begins voluntary recall of Poligrip products containing zinc

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

POZEN reports net loss of $6.9M for year ended December 31, 2009

Intercell AG's revenues for full year 2009 increase 10.6%

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Adolor announces $14.6M net product sales of ENTEREG for year ended December 31, 2009

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Senate, FDA reports increasing concerns about controversial diabetes drug

UCSF professor receives 2010 AADR Distinguished Scientist Award

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Parker Waichman Alonso applauds GSK for deciding to stop manufacturing denture adhesive products made with zinc

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News